AngioDynamics, Inc.: updates and filings

ANGONASDAQHealthcare · Surgical & Medical Instruments & Apparatus

Price

$11.78

November 16, 2026Market cap $495M

What Ploutos Investor adds for AngioDynamics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from FY2010
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Next results

in 48 daysAround Jan 4, 2027 · for Q2 2027

last Oct 8, 2026next Jan 4, 2027

An estimate from when it has reported before, which has been regular. The company announces the date itself.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Jul 14, 2026 latest annualOct 8, 2026 latest quarterly
  • Nov 16, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Oct 8, 2026Quarterly reportfor the period to Aug 31, 2026
    Form10-Q
  • Oct 8, 2026Additional annual meeting material
    FormDEFA14A
  • Oct 8, 2026Annual meeting proxy statement
    FormDEF 14A
  • Oct 8, 2026Results of operations, Regulation FD disclosure
    Form8-K
  • Oct 8, 2026Material agreement entered, officer or director change
    Form8-K
  • Sep 29, 2026Annual report (amendment)for the period to May 31, 2026
    Form10-K/A
  • Sep 29, 2026Annual report (amendment)for the period to May 31, 2026
    Form10-K/A
  • Jul 14, 2026Annual reportfor the period to May 31, 2026
    Form10-K
  • Jul 14, 2026Results of operations, Regulation FD disclosure
    Form8-K
  • May 15, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Apr 23, 2026Other material events
    Form8-K
  • Apr 2, 2026Quarterly reportfor the period to Feb 28, 2026
    Form10-Q
  • Apr 2, 2026Results of operations, Regulation FD disclosure
    Form8-K
  • Mar 26, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Feb 13, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Feb 10, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Feb 9, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Feb 3, 2026Officer or director change
    Form8-K
  • Jan 14, 2026Regulation FD disclosure
    Form8-K
  • Jan 8, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Jan 6, 2026Quarterly reportfor the period to Nov 30, 2025
    Form10-Q
  • Jan 6, 2026Results of operations, Regulation FD disclosure
    Form8-K
  • Nov 14, 2025Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 12, 2025Shareholder vote
    Form8-K

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Mar 5, 2004.

The full analysis

What do AngioDynamics's filings show?

The filings are where every one of AngioDynamics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.